Trelegy ellipta and Plaquenil drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trelegy ellipta and Plaquenil. Common interactions include injection site erythema among females and infusion site discomfort among males.

The phase IV clinical study analyzes what interactions people who take Trelegy ellipta and Plaquenil have. It is created by eHealthMe based on reports of 45 people who take Trelegy ellipta and Plaquenil from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

45 people who take Trelegy ellipta and Plaquenil together, and have interactions are studied.


What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 16,508 Trelegy ellipta users for its effectiveness, alternative drugs and more.

What is Plaquenil?

Plaquenil has active ingredients of hydroxychloroquine sulfate. It is often used in systemic lupus erythematosus. eHealthMe is studying from 83,227 Plaquenil users for its effectiveness, alternative drugs and more.

Number of Trelegy ellipta and Plaquenil reports submitted per year:

Trelegy ellipta and Plaquenil drug interactions.

Common Trelegy Ellipta and Plaquenil drug interactions by gender *:

female:

  1. Injection site erythema
  2. Injection site pain
  3. Injection site pruritus
  4. Malaise
  5. Mental status changes
  6. Migraine
  7. Pneumonia
  8. Acute respiratory failure
  9. Pain
  10. Fall

male:

  1. Infusion site discomfort
  2. Pain
  3. Abdominal discomfort
  4. Abdominal pain
  5. Blister
  6. Contusion
  7. General physical health deterioration
  8. Ill-defined disorder
  9. Pain in extremity
  10. Renal mass

Common Trelegy Ellipta and Plaquenil drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Spinal fusion surgery
  2. Wound dehiscence
  3. Wound infection
  4. Amyotrophic lateral sclerosis
  5. Infection
  6. Sinus node dysfunction

50-59:

  1. Pain
  2. Acute respiratory failure
  3. Amnesia
  4. Asthma
  5. Blood glucose increased
  6. Bronchiectasis
  7. Bronchitis
  8. Colitis
  9. Diverticulitis
  10. Dry eye

60+:

  1. Acute respiratory failure
  2. Sepsis
  3. Chronic obstructive pulmonary disease
  4. Erythema
  5. Headache
  6. Rash pustular
  7. Dysgraphia
  8. Mobility decreased
  9. Upper limb fracture
  10. Wrist fracture

Common conditions people have *:

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 13 people, 28.89%
  2. Immunodeficiency Common Variable: 12 people, 26.67%
  3. Asthma: 9 people, 20.00%
  4. High Blood Pressure: 6 people, 13.33%
  5. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 5 people, 11.11%
  6. Pain: 4 people, 8.89%
  7. High Blood Cholesterol: 4 people, 8.89%
  8. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 6.67%
  9. Immune System Disorder: 3 people, 6.67%
  10. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Trelegy ellipta and Plaquenil?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Trelegy ellipta and Plaquenil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Trelegy ellipta interactions:

Browse all interactions between Trelegy ellipta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Plaquenil interactions:

Browse all interactions between Plaquenil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on fluticasone furoate; umeclidinium bromide; vilanterol trifenatate and hydroxychloroquine sulfate (the active ingredients of Trelegy ellipta and Plaquenil, respectively), and Trelegy ellipta and Plaquenil (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Trelegy ellipta and Plaquenil.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: